XML 52 R40.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2020
Jun. 30, 2020
Dec. 31, 2019
Disaggregation Of Revenue [Line Items]      
Revenue $ 13,384 $ 20,462  
Accounts receivable 1,786 1,786 $ 813
Neurocrine Biosciences [Member]      
Disaggregation Of Revenue [Line Items]      
Accounts receivable 1,467 1,467  
Deferred revenue 12,692 12,692  
Neurocrine Biosciences [Member] | Collaboration Revenue [Member]      
Disaggregation Of Revenue [Line Items]      
Revenue 13,384 20,462  
Exclusive License to XEN901 and Exclusive License to DTCs [Member] | Neurocrine Biosciences [Member] | Collaboration Revenue [Member]      
Disaggregation Of Revenue [Line Items]      
Revenue 11,523 17,285  
Development Services Under the Initial Development Program For DTCs [Member] | Neurocrine Biosciences [Member] | Collaboration Revenue [Member]      
Disaggregation Of Revenue [Line Items]      
Revenue 393 475  
Research And Development Funding | Neurocrine Biosciences [Member] | Collaboration Revenue [Member]      
Disaggregation Of Revenue [Line Items]      
Revenue $ 1,468 $ 2,702  
License and Collaboration Agreement [Member] | Neurocrine Biosciences [Member]      
Disaggregation Of Revenue [Line Items]      
Upfront payment received in cash     30,000
Upfront payment received in equity investment     20,000
Equity investment measured at fair value     16,667
Collaborate agreement premium related to equity investment     3,333
Transaction price allocated to performance obligations     $ 33,333
Percentage of option to co-fund development costs upon achievement of certain milestones     50.00%
License and Collaboration Agreement [Member] | Exclusive License to XEN901 and Exclusive License to DTCs [Member] | Neurocrine Biosciences [Member]      
Disaggregation Of Revenue [Line Items]      
Transaction price allocated to performance obligations     $ 28,807
License and Collaboration Agreement [Member] | Development Services Under the Initial Development Program For DTCs [Member] | Neurocrine Biosciences [Member]      
Disaggregation Of Revenue [Line Items]      
Transaction price allocated to performance obligations     $ 4,526